Researchers at the Mucosal Immunology and Biology Research Center at MassGeneral Hospital for Children (MGHfC) have discovered novel genes and pathways related to early stages in the development of celiac disease and the ongoing inflammation and comorbidities associated with the condition. he findings, published in PLOS One, include analyses of RNA sequences in duodenal biopsies from individuals with and without celiac disease and are consistent with many previously described pathways in the development of celiac disease.
Total 57 genes associated with this autoimmune condition
“We know that celiac disease is a multifactorial disease with about 57 genes; associated with this autoimmune condition. So, by performing RNA sequencing, we have uncovered additional genetic ‘signatures’; and moved closer to identifying targets for future therapeutic agents; in celiac disease and possibly other autoimmune conditions;” says Maureen Leonard, MD, clinical director of the Center for Celiac Research and Treatment at MGHfC; an instructor in Pediatrics at Harvard Medical School and first author of the study.
Three top perturbed pathways in the active celiac group
“The identified genes activated three major pathways: innate immunity; gut permeability and differentiation in cell maturation;” says Alessio Fasano, MD, director of the Center for Celiac Research and Treatment at MGHfC; a professor of Pediatrics at Harvard Medical School and senior author of the PLOS One report. “We can confirm that these functions are instrumental; when you develop celiac disease.” Expression of some of the genes returned to normal when patients were; placed on a gluten-free diet; he notes in conclusion, and some did not. Fasano notes that this finding could provide some insight into why some people have persistent intestinal damage even after following a strict gluten-free diet.
So, from the enormous array of data generated, researchers chose to focus on functional pathways that were significantly different between the active celiac group and those in remission. However, two of the three top perturbed pathways in the active celiac group involved signaling by cytokines and chemokines, which are known as the immune system’s “first responders” and markers of inflammation in innate immunity in the early stages of disease development. So, the researchers also found evidence to suggest that the risk of co-morbid autoimmune disorder may be high in active celiac disease, as pathways for type 1 diabetes, lupus and autoimmune thyroid disease also were upregulated.